Literature DB >> 12952178

SDF-1 increases recruitment of osteoclast precursors by upregulation of matrix metalloproteinase-9 activity.

Xuefeng Yu1, Patricia Collin-Osdoby, Philip Osdoby.   

Abstract

Although chemokines play essential roles in the trafficking and homing of many circulating hematopoietic cell types, their potential influences on osteoclast (OC) recruitment or bone remodeling are not well known. Therefore, chemokine receptor expression was analyzed by RNase protection assay during OC formation induced by RANKL in a murine mononuclear cell line (RAW 264.7). Relatively high CXCR4 expression was detected in RAW cells (pre-OCs), whereas CXCR4 levels were downregulated during RAW-OC development. SDF-1, the unique ligand for CXCR4, stimulated RAW cell production of matrix metalloproteinase (MMP)-9 activity, a matrix-degrading enzyme essential for pre-OC migration into the developing bone marrow cavity. Induced MMP-9 activity in RAW cells was associated with their increased MMP-dependent transmigration through a collagen gel in response to SDF-1. We conclude that SDF-1 stimulation of MMP-9 activity in pre-OCs may be a key aspect of their recruitment to bone and migration within the marrow to sites for OC differentiation and bone resorption.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12952178

Source DB:  PubMed          Journal:  Connect Tissue Res        ISSN: 0300-8207            Impact factor:   3.417


  8 in total

1.  Chemokine and chemokine receptor expression during colony stimulating factor-1-induced osteoclast differentiation in the toothless osteopetrotic rat: a key role for CCL9 (MIP-1gamma) in osteoclastogenesis in vivo and in vitro.

Authors:  Meiheng Yang; Geneviève Mailhot; Carole A MacKay; April Mason-Savas; Justin Aubin; Paul R Odgren
Journal:  Blood       Date:  2005-11-22       Impact factor: 22.113

2.  Histochemical evidence of zoledronate inhibiting c-src expression and interfering with CD44/OPN-mediated osteoclast adhesion in the tibiae of mice.

Authors:  Hongrui Liu; Jian Cui; Jing Sun; Juan Du; Wei Feng; Bao Sun; Juan Li; Xiuchun Han; Bo Liu; Kimimitsu Oda; Norio Amizuka; Minqi Li
Journal:  J Mol Histol       Date:  2015-05-13       Impact factor: 2.611

3.  Pro-oxidant status and matrix metalloproteinases in apical lesions and gingival crevicular fluid as potential biomarkers for asymptomatic apical periodontitis and endodontic treatment response.

Authors:  Andrea Dezerega; Sonia Madrid; Verónica Mundi; María A Valenzuela; Mauricio Garrido; Rodolfo Paredes; Jocelyn García-Sesnich; Ana V Ortega; Jorge Gamonal; Marcela Hernández
Journal:  J Inflamm (Lond)       Date:  2012-03-21       Impact factor: 4.981

4.  Environmental Factors Impacting Bone-Relevant Chemokines.

Authors:  Justin T Smith; Andrew D Schneider; Karina M Katchko; Chawon Yun; Erin L Hsu
Journal:  Front Endocrinol (Lausanne)       Date:  2017-02-14       Impact factor: 5.555

5.  ERα Signaling in a Subset of CXCL12-Abundant Reticular Cells Regulates Trabecular Bone in Mice.

Authors:  Julia M Scheffler; Karin L Gustafsson; Aidan Barrett; Carmen Corciulo; Christina Drevinge; Alicia M Del Carpio Pons; Piotr Humeniuk; Cecilia Engdahl; Jan-Åke Gustafsson; Claes Ohlsson; Hans Carlsten; Marie K Lagerquist; Ulrika Islander
Journal:  JBMR Plus       Date:  2022-06-17

6.  Bone marrow microenvironment and tumor progression.

Authors:  Christophe F Chantrain; Olivier Feron; Etienne Marbaix; Yves A DeClerck
Journal:  Cancer Microenviron       Date:  2008-05-07

7.  Membrane localization of membrane type 1 matrix metalloproteinase by CD44 regulates the activation of pro-matrix metalloproteinase 9 in osteoclasts.

Authors:  Meenakshi A Chellaiah; Tao Ma
Journal:  Biomed Res Int       Date:  2013-07-28       Impact factor: 3.411

8.  Correlation between Peri-Implant Marginal Bone Loss Progression and Peri-Implant Sulcular Fluid Levels of Metalloproteinase-8.

Authors:  Renzo Guarnieri; Alessio Zanza; Maurilio D'Angelo; Dario Di Nardo; Andrea Del Giudice; Alessandro Mazzoni; Rodolfo Reda; Luca Testarelli
Journal:  J Pers Med       Date:  2022-01-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.